Hepatitis B: Are We Edging Closer to a Cure?

Why It Matters

Therapies that deliver a functional cure could sharply cut liver‑related morbidity and mortality, easing the global health burden while unlocking sizable market opportunities for biotech firms.

Key Takeaways

• 254 million infected globally, 1.1 million deaths 2022.
• Functional cure defined by undetectable HBV DNA and HBsAg loss.
• China's Pegbing shows 31.4% functional cure in trial.
• Bepirovirsen phase 3 meets endpoints, targeting FDA approval.
• Combination therapies seen as future path to HBV cure.

Pulse Analysis

Hepatitis B remains one of the world’s most pressing infectious diseases, with the World Health Organization estimating 254 million chronic carriers and over one million deaths annually. Unlike hepatitis C, which can be eradicated with short‑course direct‑acting antivirals, HBV persists as covalently closed circular DNA (cccDNA) in liver cells, making a sterilizing cure elusive. The clinical community therefore focuses on a functional cure—sustained suppression of viral replication and loss of surface antigen (HBsAg)—as a realistic target that could halt progression to cirrhosis and hepatocellular carcinoma while preserving patient quality of life.

Momentum accelerated in 2025 when China’s Amoytop Biotech secured approval for Pegbing, the first domestically developed drug aimed at a functional cure, reporting a 31.4 % HBsAg clearance rate after 24 weeks of combination therapy. Across the Pacific, GSK and Ionis’s antisense oligonucleotide bepirovirsen completed two global phase 3 trials involving more than 1,800 patients, achieving statistically significant functional cure rates versus standard of care. Parallel programs such as AusperBio’s AHB‑137 and Helmholtz’s therapeutic vaccine TherVacB are advancing through phase 3 and phase 1b/2a studies, expanding the pipeline of finite‑duration, immune‑modulating candidates.

Despite these breakthroughs, the path to a widely accessible cure is fraught with scientific and regulatory hurdles. The heterogeneous nature of cccDNA reservoirs and the immune exhaustion observed in chronic infection demand combinatorial regimens that pair potent antivirals with immunomodulators, yet optimal dosing schedules and safety profiles remain under investigation. Successful approval of bepirovirsen or similar agents would not only transform clinical practice but also stimulate substantial investment in HBV R&D, reshaping the pharmaceutical landscape and offering a tangible reduction in global liver disease burden.